05766846 is referenced by 126 patents and cites 8 patents.

Soluble .beta.-amyloid peptide (.beta.AP) is measured in biological fluids at very low concentrations, typically in the range from 0.1 ng/ml to 10 ng/ml. The measurement of .beta.AP concentrations in animals or conditioned medium from cultured cells can be used for drug screening, where test compounds are administered to the animals or exposed to the cultured cells and the accumulation of .beta.AP in the animal or culture medium observed. It has been found that elevated levels of .beta.AP in body fluids, such as blood and cerebrospinal fluid, is associated with the presence of a .beta.AP-related condition in a patient, such as Alzheimer's Disease. Methods for diagnosing and monitoring .beta.AP-related conditions comprise measuring the levels of .beta.AP in such body fluids from a patient.

Title
Methods of screening for compounds which inhibit soluble .beta.-amyloid peptide production
Application Number
911647
Publication Number
5766846
Application Date
June 17, 1993
Publication Date
June 16, 1998
Inventor
Dennis J Selkoe
Jamaica Plain
MA, US
Michael G Schlossmacher
Vienna
AT
Agent
Townsend and Townsend and Crew
Assignee
Eli Lilly and Company
IN, US
Athena Neurosciences
CA, US
IPC
G01N 33/53
View Original Source